



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/937,414 01/30/2002		Hironobu Murase	4296-146 US	2128	
75	90 08/10/2004	· ·	EXAMINER		
Diane Dunn McKay Mathews Collins Shepherd & Gould Suite 306			MCINTOSH III, TRAVISS C		
			ART UNIT	PAPER NUMBER	
100 Thanet Circle Princeton, NJ 08540			1623	1623	
			DATE MAILED: 08/10/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		· · · · · · · · · · · · · · · · · · ·
	Application No.	Applicant(s)
· · · · · · · · · · · · · · · · · · ·	09/937,414	MURASE ET AL.
Office Action Summary	Examiner	Art Unit
	Traviss C McIntosh	1623
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period who is reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply within the statutory minimum of thirty (3 vill apply and will expire SIX (6) MONTH; cause the application to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this communication. IDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 30 Ma	<u>arch 2004</u> .	
2a) This action is FINAL . 2b) ⊠ This	action is non-final.	
3) Since this application is in condition for allowar	ice except for formal matters	s, prosecution as to the merits is
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 1	1, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) 10-21 is/are pending in the application	1.	
4a) Of the above claim(s) is/are withdraw		
5) Claim(s)is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8)⊠ Claim(s) <u>10-21</u> are subject to restriction and/or	election requirement.	
Application Papers		
9) The specification is objected to by the Examine	r.	
10) The drawing(s) filed on is/are: a) acce		the Examiner.
Applicant may not request that any objection to the	drawing(s) be held in abeyance	. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s)	is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Ex	aminer. Note the attached C	Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 1	19(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents	have been received.	
2. Certified copies of the priority documents	s have been received in App	lication No
3. Copies of the certified copies of the prior	ity documents have been re	ceived in this National Stage
application from the International Bureau	(PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list of	of the certified copies not red	ceived.
Attachment(s)		
1) Notice of References Cited (PTO-892)		nmary (PTO-413)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 		Mail Date rmal Patent Application (PTO-152)
Paper No(s)/Mail Date	6) Other:	a. , atom , pproduor (i 10-102)

Application/Control Number: 09/937,414

Art Unit: 1623

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 10-13, drawn to methods of treating cutaneous inflammation by administering the chromanol glycoside of formula 1.

Group II, claim(s) 14-17, drawn to methods of treating the deposition of pigment or whitening the skin of a mammal by administering the chromanol glycoside of formula 1.

Group III, claim(s) 18-19, drawn to treating the formation of wrinkles and sags in the skin by administering the chromanol glycoside of formula 1.

Group IV, claim(s) 20-21, drawn to promoting growth of cells in mammals by administering the chromanol glycoside of formula 1.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the "special technical feature" of group I is the use of the chromanol glycosides of formula 1, however the chromanol glycosides of formula 1 are known in the art, as seen by JP-A-07-118,287, JP-A-09-249,688, and JP-A-11-21,199, as well as by Murase et al., US Patent 5,478,812, and thus do not make a contribution over the prior art. Therefor, the special technical feature of group I is the use of the chromanol glycoside of formula 1 for treating cutaneous inflammation, which is different than the use for treating the

Application/Control Number: 09/937,414

Art Unit: 1623

deposition of pigment as in group II, and treating the formation of wrinkles and sags in the skin of group III, and to promoting growth of cells in mammals of group IV.

A telephone call was made to Patrick Higgins on August 4, 2004 to request an oral election to the above restriction requirement, but did not result in an election being made, as the examiner was only able to leave a message.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

The examiner apologizes for any problems that the instantly set forth restriction requirement may cause. The indication that the above methods are not being based on the chromanol glycosides antioxidant activity necessitated the instant restriction requirement.

Upon election, the examiner will discuss the arguments set forth in applicants response filed March 30, 2004.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Traviss C McIntosh whose telephone number is 571-272-0657. The examiner can normally be reached on M-F 9:30-6:00.

Art Unit: 1623

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Traviss C. McIntosh III August 5, 2004 James O. Wilson

Supervisory Patent Examiner

Art Unit 1623